Concert Pharmaceuticals Inc

NASDAQ:CNCE   3:59:42 PM EDT
4.05
-0.06 (-1.46%)
Products, Regulatory, Other Pre-Announcement

Concert Pharmaceuticals Initiates Thrive-Aa2 Phase 3 Clinical Trial Evaluating Ctp-543 For Alopecia Areata

Published: 05/27/2021 11:17 GMT
Concert Pharmaceuticals Inc (CNCE) - Concert Pharmaceuticals Initiates Thrive-aa2 Phase 3 Clinical Trial Evaluating Ctp-543 for Alopecia Areata.
Concert Pharmaceuticals Inc - Expects to Report Topline Results From Thrive-aa2 in Second Half of 2022.
Concert Pharmaceuticals - Positive Results From Two Phase 3 Trials Could Serve As Basis for Submitting NDA to FDA in Early 2023 for Ctp-543.